Impact of DEHP exposure on female reproductive health: Insights into uterine effects
Por:
Martínez-Ibarra A., Cerbón M., Martínez-Razo L.D., Morales-Pacheco M., Torre-Villalvazo I., Kawa S., Rodríguez-Dorantes M.
Publicada:
1 ene 2024
Ahead of Print:
1 feb 2024
Resumen:
Several endocrine disrupting compounds released from plastics, including polyfluoroalkyl substances, bisphenols, flame retardants, phthalates and others, are of great concern to human health due to their high toxicity. This review discusses the effects of di-(2-ethylhexyl) phthalate (DEHP), the most common member of the phthalate family, on female reproduction. In vitro and in vivo studies link DEHP exposure to impaired hypothalamic-pituitary-ovarian s (HPO) axis function, alteration of steroid-hormone levels and dysregulation of their receptors, and changes in uterine morphophysiology. In addition, high urinary DEPH levels have been associated with several reproductive disorders in women, including endometriosis, fibromyoma, fetal growth restriction and pregnancy loss. These data suggest that DEHP may be involved in the pathophysiology of various female reproductive diseases. Therefore, exposure to these compounds should be considered a concern in clinician surveillance practices for women at reproductive age and should be regulated to protect their health and that of their progeny. © 2024 Elsevier B.V.
Filiaciones:
Martínez-Ibarra A.:
Facultad de Química, Universidad Nacional Autónoma de México, Ciudad de México, 04510, Mexico
Cerbón M.:
Facultad de Química, Universidad Nacional Autónoma de México, Ciudad de México, 04510, Mexico
Martínez-Razo L.D.:
Facultad de Química, Universidad Nacional Autónoma de México, Ciudad de México, 04510, Mexico
Morales-Pacheco M.:
Laboratorio de Oncogenómica, Instituto Nacional de Medicina Genómica, Ciudad de México, 14610, Mexico
Torre-Villalvazo I.:
Departamento de Fisiología de la Nutrición, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico
Kawa S.:
Dirección General del Hospital General Dr. Manuel Gea González, Ciudad de México, Mexico
Rodríguez-Dorantes M.:
Laboratorio de Oncogenómica, Instituto Nacional de Medicina Genómica, Ciudad de México, 14610, Mexico
|